Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) in the first study of a cardiac myosin inhibitor (CMI) in adolescents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback